mitolactol and Leukemia--Myeloid

Topics: Acute Disease; Adult; Aged; Breast Neoplasms; Female; Humans; Leukemia, Myeloid; Middle Aged; Mitolactol; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors

A combination of cytostatics--Rubomycin (Medexport), Alcysten (Spofa) and LANVIS (Wellcome) was used to treat 44 patients with the diagnosis AML. A total of 66% CR was achieved. The median duration of CR was 15 months and the median of survival of patients with CR was 25 months. 20% of the patients died in induction mostly from infectious complications. The authors assume that this combination with the use of the Czech preparation Alcysten and the Soviet preparation Rubomycin is suitable induction treatment in AML. Treatment, however, calls for perfect supporting therapy and therefore should by concentrated in selected departments.

Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Leukemia, Myeloid; Middle Aged; Mitolactol; Tamoxifen

In a 18 years old, Ph1 negative woman a lymphoblastic lymphoma developed after 16 months of treatment for juvenile form of CGL. In the course of the disease we observed twice the myeloblastic transformation and once the low differentiated transformation of CGL. Based on available methods we are not in a position to exclude a particular form of lymphoblastic transformation of CGL involving lymph nodes without leukaemic blood picture.

Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; DNA Nucleotidylexotransferase; Doxorubicin; Female; Humans; Karyotyping; Leukemia, Myeloid; Lymph Nodes; Lymphoma, Non-Hodgkin; Mitolactol; Prednisone; Vincristine

The authors give a summarizing report about mitolactol treatments performed in Hungary. As a single-agent therapy the drug was administered in two forms: (1) every-day therapy, 5 mg/kg/day, (2) push therapy, 10 mg/kg every 5th day or 15 mg/kg every 7th day, in a total dose of 100 mg/kg in both administration forms. Out of the solid tumours the squamous cell cancers proved to be the most responsive to mitolactol therapy: first of all in tumours of the head and neck and of the lung. The study also reports the preliminary results of polychemotherapeutical protocols containing mitolactol now in progress: (1) bleomycin + mitolactol (Bristol protocol), (2) carminomycin + mitolactol and (3) adriamycin + mitolactol.

Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Leukemia, Myeloid; Mitolactol

Topics: Anemia; Azauridine; Blood Cell Count; Blood Platelets; Bone Marrow Examination; Busulfan; Cell Transformation, Neoplastic; Humans; Hydroxyurea; Karyotyping; Leukemia, Myeloid; Mitolactol; Nitrogen Mustard Compounds; Phenylalanine; Primary Myelofibrosis; Prognosis; Splenomegaly; Thrombocytosis